)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Dirui Industrial Co
Dirui Industrial Co (300396) investor relations material
Dirui Industrial Co Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 revenue was ¥221.95m, up 88.00% YoY; YTD revenue reached ¥630.48m, up 34.50%, driven mainly by domestic growth.
YTD net loss attributable to shareholders was ¥15.62m, versus ¥87.25m in the prior-year period; impairment charges and higher finance costs weighed on results.
Excluding impairment and other cited impacts, Q3 performance improved; management cited adequate funding and stronger receivables collection.
Financial highlights
Q3 net loss attributable to shareholders was ¥23.22m; adjusted net loss was ¥24.63m.
YTD adjusted net loss was ¥24.24m; YTD net loss attributable to shareholders was ¥15.62m.
YTD operating cash flow was negative ¥127.46m, versus negative ¥58.21m in the prior-year period; refunds of previously received contract payments were a key driver.
YTD revenue increased ¥161.73m YoY; total assets were ¥2.46bn, down 11.20% from year-end.
Outlook and guidance
Priorities include advancing high-end instruments in benchmark hospitals and tier-three hospitals, and building reagent revenue following international installations.
Management plans to deepen finance-operations integration, intelligent seal controls and full-lifecycle contract management to reinforce remediation and efficiency.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Dirui Industrial Co
- Revenue up 16.5% and net profit positive; compliance and AI innovation drive future growth.300396
Q2 2026 - 2025 reversed to a net loss on falling domestic sales and impairments, with auditor's qualified opinion.300396Q4 2025
- Q1 2026 saw a net loss and lower revenue, driven by higher R&D, compliance actions, and FX impacts.300396Q1 2026
- Net profit plunged 145% year-over-year amid revenue decline and domestic market headwinds.300396Q3 2025
- Revenue and profit fell sharply, but cash flow and cost controls showed improvement.300396Q1 2025
- Revenue dropped 60% year-over-year, leading to a net loss, with international sales as a bright spot.300396Q2 2025
- Q3 net profit dropped 62.28% year-over-year as revenue and margins declined.300396Q3 2024
- Revenue up 26.38% year-over-year, net profit rises 2.12% to ¥165.24 million.300396Q2 2024
- Revenue and profit declined sharply, with a focus on reagent sales and cash flow for 2025.300396Q4 2024
Next Dirui Industrial Co earnings date
Q4 202616 Apr, 2027
Dirui Industrial Co
Next Dirui Industrial Co earnings date
Q4 202616 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Dirui Industrial Co., Ltd. is a Chinese company specializing in the development, manufacture, and sale of medical diagnostic equipment and related reagents. Founded in 1992, the company produces a wide range of diagnostic products, including clinical chemistry analyzers, urine analyzers, hematology analyzers, immunoassay analyzers, and coagulation analyzers. The company is headquartered in Changchun, Jilin, and its shares are listed on the Shenzhen Stock Exchange.